Journal: PLoS ONE

Article Title: The POZ-ZF Transcription Factor Kaiso (ZBTB33) Induces Inflammation and Progenitor Cell Differentiation in the Murine Intestine

doi: 10.1371/journal.pone.0074160

Figure Lengend Snippet: Cell proliferation was evaluated by Ki67 ( A ) and Cyclin D1 ( B ) staining. Both markers exhibited reduced staining in Kaiso Tg /+ mice compared to their Non-Tg siblings. Reduced CyclinD1 expression was also confirmed by immunoblot analysis of 3 different mice intestines ( C ). ** represents significance.

Article Snippet: Antibodies used were as follows: anti-Kaiso rabbit polyclonal antibody at a 1∶30,000 dilution, anti-Cyclin D1 rabbit polyclonal antibody (US Biological) at a 1∶5,000 dilution, anti-β-actin mouse monoclonal antibody (Sigma Aldrich) at a 1∶30,000 dilution.

Techniques: Staining, Expressing, Western Blot

Journal: Oncology Reports

Article Title: Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway

doi: 10.3892/or.2018.6198

Figure Lengend Snippet: The gemcitabine-erlotinib (E+G) combination group inhibits the activity of the JAK-STAT pathway, as well as the expression of downstream HIF-1α, cyclin D1 and p53. (A and B) The protein levels of phosphorylated STAT3 Tyr 705 (p-STAT3 Tyr 705 ), HIF-1α, p53, cyclin D1 in BxPC-3 and PANC-1 cells were analyzed by western blotting, respectively. (C and D) The protein expression of p-STAT3 Tyr 705 , HIF-1α, p53, cyclin D1 in BxPC-3 and PANC-1 cells was calculated using one-way ANOVA. *P<0.05 denotes the controls vs. the treatment groups. # P<0.05 denotes the monotherapy (E or G) vs. the combination (E+G) groups. (E) Phosphorylation levels of JAK1 (Tyr 1022 ), JAK2 (Tyr 221 ), JAK3(Tyr 981 ) and STAT3 (Tyr 701 ) in BxPC-3 and PANC-1 cells were analyzed by western blotting, respectively. (F and G) The protein intensity of phospho-JAK1 (p-JAK1), p-JAK2 and p-JAK3 in BxPC-3 and PANC-1 cells was calculated using one-way ANOVA. # P<0.01; *P<0.05. (H) The protein intensity of p-STAT1 in BxPC-3 and PANC-1 cells was assessed using one-way ANOVA. # P<0.01, *P<0.05. E, erlotinib; G, gemcitabine.

Article Snippet: The following primary antibodies were used: anti-JAK1 (rabbit polyclonal; cat. no. AF5012), phospho-JAK1 (Tyr 1022 ) (rabbit polyclonal; cat. no. AF2012), anti-JAK2 (rabbit polyclonal; cat. no. AF6022), phospho-JAK2 (Tyr 221 ) (rabbit polyclonal; cat. no. AF3023), anti-JAK3 (mouse monoclonal; cat. no. BF0256), phospho-JAK3 (Tyr 981 ) (rabbit polyclonal; cat. no. AF8160), phospho-STAT1 (Tyr 701 ) (rabbit polyclonal; cat. no. AF3300) and anti-STAT1 (rabbit polyclonal; cat. no. AF6300) were all purchased from Affinity Biosciences (Cambridge, UK); anti-STAT3 (rabbit monoclonal; cat. no. ab76315), and anti-pSTAT3 Try 705 (rabbit monoclonal; cat. no. ab68153) were obtained from Abcam (Cambridge, MA, USA); anti-HIF-1α (rabbit polyclonal; cat. no. BS3514) and anti-cyclin D1 (rabbit polyclonal; cat. no. BS6532) were purchased from Bioworld Technology Co., Ltd. (Nanjing, China); anti-p53 (rabbit, monoclonal; cat. no. 2527) was acquired from Cell Signaling Technology, Inc. (Danvers, MA, USA); while GAPDH was purchased from EarthOx Life Sciences (Millbrae, CA, USA).

Techniques: Activity Assay, Expressing, Western Blot